Drug Trial Radar · NCT00517712
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Aug 17, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Jun 2004
Primary completion
Not stated
Study completion Jul 2009
Sponsor
- Lead sponsor
- Christian Medical College, Vellore, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Science and Technology, India
- First posted
- Aug 17, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is very limited data on the use of arsenic trioxide in newly diagnosed patients with acute promyelocytic leukemia. The use of arsenic trioxide was limited to relapsed patients mainly because of the superior efficacy of ATRA as primary therapy for newly diagnosed APML. Though the early study by Niu et al showed 72% remission rates in 11 newly diagnosed patients, the role of arsenic trioxide as primary therapy was limited by the hepatic toxicity seen in this study. Studies from our centre have shown remission rates of 70-75% in newly diagnosed patients with acute promyelocytic leukemia. There was no major toxicity seen related to the administration of arsenic trioxide. Follow up data on these patients continue to show long term remission rates above 70%. These remission rates are similar to the data available in patients with acute promyelocytic leukemia treated with ATRA. Lu et al studied 19 patients treated with oral arsenic (Tetra-arsenic tetra-sulfide) wherein 84% achieved hematological remission with disease free survival of 76% at 3 years. Studies from other groups using arsenic trioxide alone or in combination with ATRA have shown similar remission rates. Arsenic trioxide as primary therapy for patients with newly diagnosed acute promyelocytic leukemia is a very attractive treatment option for developing countries mainly because of the low cost involved along with the favorable toxicity profile. However long term remission data is still not available and the ideal course and duration of treatment still needs to be defined. This multi-center study aims to further clarify the efficacy of this agent in the treatment of newly diagnosed cases of acute promyelocytic leukemia and to study the optimal maintenance regimen.
Conditions
- Acute Promyelocytic Leukemia
Interventions
Single agent arsenic trioxideDrug
duration of maintenance therapy, 6 months versus 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure complete hematological remission rateTime frame: 60 days
- Measure complete molecular remission rateTime frame: 3 months
- Measure duration of responseTime frame: 5 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Kidwai Memorial Institute of Oncology
Bangalore, Karnataka, India · Not yet recruiting
St. Johns Hospital
Bangalore, Karnataka, India · Recruiting
Regional Cancer Center
Trivandrum, Kerala, India · Recruiting
Prince Aly Khan Hospital
Mumbai, Maharashtra, India · Not yet recruiting
KEM Hospital
Mumbai, Maharashtra, India · Recruiting
Tata Memorial Hospital
Mumbai, Maharashtra, India · Recruiting
Sahyadri Speciality Hospital
Pune, Maharashtra, India · Recruiting
Institute Rotary Cancer Hospital
New Delhi, New Delhi, India · Recruiting
Netaji Subhash Chandra Bose Cancer Research Institute
Kolkata, West Bengal, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.